Updated 04 March 2014

Better HIV antibodies may lead to new vaccine

South African scientists working with US researchers have found a method to develop antibodies that will kill multiple strains of the HIV virus.

A method for developing antibodies with the ability to kill multiple strains of the human immunodeficiency virus (HIV) was announced by South African scientists working with US researchers.

A small number of HIV-infected people developed the antibodies, but are not helped by them because they are unable to kill the wide range of HIV, said National Institute of Communicable Diseases virology head Prof Lynn Morris.

Read: HIV antibody breakthrough

Broadly neutralising antibodies

"We need to understand how to make better antibodies to HIV. We can learn that from people who are already infected, because a small proportion of them [infected people] make these broadly neutralising antibodies," she told reporters in Johannesburg.

"There has been a lot of focus on the individuals that make this special type of antibodies. That information, we hope, is going to help us make a better vaccine to HIV."

A KwaZulu-Natal woman, identified in the research as CAP256, had responded to HIV infection by making the broadly neutralising antibodies.

The research team had identified these antibodies in her blood and duplicated them by cloning them in a laboratory.

A new vaccine

The cloned antibodies were then used in a series of experiments to clarify the pathway followed by CAP256's immune system to make the HIV-combating antibodies.

The identification and successful cloning of the antibodies had enabled researchers to make large quantities for further testing, similar to the way a medicine used to prevent or treat HIV would be tested.

"What we have to do now is to design a vaccine that is able to engage with the rare B-cells. If we are able to do that, we should be able to make a vaccine that will take months for people to develop the immunity against HIV," said Morris.

Read: Antibodies kill 88% of HIV types

Sometimes referred to as the body's army, antibodies are specialised cells produced by B-cells as a primary immune defence. They are used by the body for either treatment or prevention.

Morris said CAP256's antibodies would be used in a sequence of pre-clinical trials in monkeys, a process which could take years to prove their efficacy.

US vaccine research centre

If successful, the research would guide HIV vaccine development. The antibodies might also be used as treatment for HIV.

The research was primarily funded by the US vaccine research centre, and the science and technology department.

The scientists worked in the "Caprisa" consortium of Aids researchers, which included the University of KwaZulu-Natal, the University of the Witwatersrand, the National Institute of Communicable Diseases, the University of Cape Town, and Columbia University in the US.

Read more:

Motsoaledi lauds HIV discovery

Swarms of antibodies could control HIV

Scientists Find Clues to How the Body Fights Off HIV



Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

HIV/Aids expert

Dr Sindisiwe van Zyl qualified at the University of Pretoria before working for an HIV/AIDS NPO in Soweto for many years. She was named one of the Mail & Guardian's Top 200 Young South Africans in 2012.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules